Copper drives prion protein phase separation and modulates aggregation.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 37922348.
- Also identified by DOI 10.1126/sciadv.adi7347 and PMC identifier 10624353.
- Licence recorded as CC BY-NC.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Prion diseases are characterized by prion protein (PrP) transmissible aggregation and neurodegeneration, which has been linked to oxidative stress. The physiological function of PrP seems related to sequestering of redox-active Cu<sup>2+</sup>, and Cu<sup>2+</sup> dyshomeostasis is observed in prion disease brain. It is unclear whether Cu<sup>2+</sup> contributes to PrP aggregation, recently shown to be mediated by PrP condensation. This study indicates that Cu<sup>2+</sup> promotes PrP condensation in live cells at the cell surface and in vitro through copartitioning. Molecularly, Cu<sup>2+</sup> inhibited PrP β-structure and hydrophobic residues exposure. Oxidation, induced by H<sub>2</sub>O<sub>2</sub>, triggered liquid-to-solid transition of PrP:Cu<sup>2+</sup> condensates and promoted amyloid-like PrP aggregation. In cells, overexpression of PrP<sup>C</sup> initially protected against Cu<sup>2+</sup> cytotoxicity but led to PrP<sup>C</sup> aggregation upon extended copper exposure. Our data suggest that PrP condensates function as a buffer for copper that prevents copper toxicity but can transition into PrP aggregation at prolonged oxidative stress.
Medical subject headings
- Prion Proteins
- Prions